- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03592082
Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Clostridium difficile (C.Diff) infection is the leading cause of hospital acquired infection and infectious diarrhea in hospitalized patients. Eradication treatment for this infection is the challenging task for clinicians due to treatment resistance developed from new hypervirulent strains. The recurrence rate of this infection is around 20% and there is high likelihood (60-70%) of another episode after index recurrence. Given constant challenges new treatment options are under study.
The purpose of this study is to examine if the addition of bismuth subsalicylate (BSS) (the active ingredient in Pepto-Bismol) 524 mg ((2) 262 mg tablets) given four times per day for 14 days to standard of care treatment of C.Diff will decrease the length of stay and decrease the time to resolution of C.Diff symptoms compared to patients who received standard of care treatment for C.Diff alone.
Bismuth subsalicylate has been used for long time in infectious diarrhea and is over the counter drug with few side effects. Studies in hamsters have shown bismuth subsalicylate to be effective in treating C.Diff. Investigators believe given cheaper cost and less side effect profile this drug is worth looking for treatment of C.Diff infection which has a huge burden on health care.
This is an open label, randomized, controlled trial. Hospitalized patients aged 18 years or older with positive stool test for C.Diff toxin will be randomized to one of two treatment groups:
Group 1 will receive standard of care treatment for C.Diff alone Group 2 will receive BSS 524 mg four times daily for 14 days along with standard of care treatment Oral antibiotic therapy will be limited to oral vancomycin 125 mg every 6 hours daily which is the standard dose for the treatment of clostridium difficile.
Length of stay and time to resolution of symptoms will be measured and compared between the two treatment groups as primary outcomes. Resolution of symptoms is defined has having < 3 diarrheal episodes in 24 hours. The study will also record episodes of recurrence, defined as the reappearance of symptoms within 8 weeks of the completion of antibiotic treatment and the resolution of initial symptoms. Recurrence rates will be compared between the two treatment groups as a secondary outcome.
Both Groups 1 & 2 will have 2 week and 8 week follow up phone calls. Group 1 participants will be called 2 weeks after consent/enrollment in the study to verify antibiotic therapy is completed, verify when/if CDiff symptoms resolved, collect data about any adverse events. Group 2 participants will be called 2 weeks after the initiation of study drug (which should be < 24 hours after consent). The visit window will start on the day the participant is scheduled to complete study drug. The purpose of the call will be to verify that both antibiotics and study drug have been completed, verify when/if CDiff symptoms resolved, and collect data about any adverse events.
Both Groups 1 and 2 participants will be called 8 weeks after the expected (or known) completion date of antibiotic therapy prescribed for the treatment of CDiff to see if CDiff symptoms have recurred and if there have been any adverse events..
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
Cooperstown, New York, United States, 13326
- Bassett Healthcare Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- Hospitalized patient with documented positive stool test for CDiff
- Able and willing to provide informed consent
Exclusion Criteria:
- Pregnancy
- Breastfeeding
- Known allergy to BSS or other salicylates, including aspirin
- History of bleeding disorder
- History of gastrointestinal bleed,
- History of gastrointestinal ulcer
- Chronic use of anticoagulants
- Chronic NSAID use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard care alone
Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
|
antibiotic therapy administered per standard protocol
|
Experimental: Standard care with Bismuth subsalicylate (BSS)
Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
|
BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of stay
Time Frame: 70 days (study period = 14 days of antibiotic treatment plus 8 weeks/56 days post treament completion)
|
number of days hospitalized after the initiation of treatment for CDiff
|
70 days (study period = 14 days of antibiotic treatment plus 8 weeks/56 days post treament completion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to resolution of symptoms
Time Frame: 70 days
|
Resolution of symptoms is defined as having < 3 diarrheal episodes in 24 hours
|
70 days
|
CDiff Recurrence
Time Frame: 70 days
|
Recurrence is defined as the reappearance of symptoms within 8 weeks of the completion of antibiotic treatment and the resolution of initial symptoms
|
70 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Abdulhadi Quadri, MD, Bassett Medical Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2089
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of PennsylvaniaTerminatedSevere Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile InfectionUnited States
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; North Carolina...CompletedClostridium DifficileUnited States
-
University Health Network, TorontoTerminatedRecurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile InfectionCanada
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
MJM BontenUniversiteit Antwerpen; Universitätsklinikum Köln; Da VolterraCompletedClostridium DifficileGermany, Spain, France, Greece, Netherlands, Romania
-
Astellas Pharma Europe Ltd.Cubist Pharmaceuticals LLCTerminatedClostridium DifficileSpain, France, Germany, Greece, Denmark, Austria, Poland
Clinical Trials on standard antibiotic therapy
-
Rigshospitalet, DenmarkHvidovre University HospitalRecruitingFebrile Urinary Tract InfectionDenmark
-
Assistance Publique - Hôpitaux de ParisAdvanz Pharma; Centre Hospitalier de Perigueux; CHU de Nantes; Centre National...RecruitingStaphylococcus Aureus Infection | Catheter BacteremiaFrance
-
US Department of Veterans AffairsCompletedUrinary Tract Infection | Spinal Cord Injury | Neurogenic BladderUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedBacterial InfectionUnited States
-
University of MiamiRecruitingVentilator Associated PneumoniaUnited States
-
Nazarbayev University Medical CenterEurasia Invest Ltd.; Ministry of Education and Science, Republic of KazakhstanCompletedAcute BronchitisKazakhstan
-
XBiotech, Inc.CompletedStaphylococcus Aureus BacteremiaUnited States
-
Spanish Society of Family and Community MedicineCompletedRespiratory Tract Infections | Infectious DiseasesSpain
-
Balgrist University HospitalRecruiting
-
Catholic University of the Sacred HeartCompletedClostridium DifficileItaly